Merck Wins Singulair Patent Battle With Teva
This article was originally published in The Pink Sheet Daily
Executive Summary
A federal court rules that broad scientific presentations do not constitute prior art in this case, a finding that gives Merck three years to consider an OTC switch.
You may also be interested in...
Merck Talks About Its Pipeline Post-Singulair
With its blockbuster asthma drug Singulair going off-patent at the end of the year, Merck is looking to a few key drugs to fill the revenue gap in the coming years, said the company at a recent Deutsche Bank Healthcare conference.
Merck Talks About Its Pipeline Post-Singulair
With its blockbuster asthma drug Singulair going off-patent at the end of the year, Merck is looking to a few key drugs to fill the revenue gap in the coming years, the company said at a recent Deutsche Bank Healthcare conference.
Nexium Patent Battle Could Switch To Generic Vs. Generic Fight
Teva obtains a license from AstraZeneca to begin marketing generic Nexium in May 2014 but may be delayed by Ranbaxy's exclusivity; Teva also withdraws appeal of ruling that upheld Merck's Singulair patent.